Dr. Steven P. Heddinger, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 707
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IA license 31496 -
Internal Medicine Physician
IA license MD-31496
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Mercyone Des Moines Medical Center Des Moines, IA
- Unitypoint Health - Des Moines Iowa Methodist Medi Des Moines, IA
- Trinity Regional Medical Center Fort Dodge, IA
- Grinnell Regional Medical Center Grinnell, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 707
- Services billed
- 91,340
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 10,600 | 24 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 7,650 | 11 |
| Injection, denosumab, 1 mg | 6,540 | 33 |
| Injection, paclitaxel, 1 mg | 5,608 | 15 |
| Injection, aprepitant, 1 mg | 5,200 | 21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,440 | 63 |
| Established patient office or other outpatient visit, 30-39 minutes | 947 | 357 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 830 | 201 |
| Injection, palonosetron hcl, 25 mcg | 790 | 42 |
| Injection, ondansetron hydrochloride, per 1 mg | 776 | 53 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 28 payments worth $576 in total to this clinician.
| AbbVie Inc. | $84.27 |
|---|---|
| Janssen Biotech, Inc. | $75.80 |
| Alexion Pharmaceuticals, Inc. | $43.47 |
| Astellas Pharma US Inc | $37.42 |
| Aveo Pharmaceuticals, Inc. | $34.10 |
| Genentech USA, Inc. | $29.00 |
| Daiichi Sankyo Inc. | $28.58 |
| Sobi, Inc | $23.66 |
| Food and Beverage | $556 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. May 12, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.